ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non–small cell lung cancer (mNSCLC) with high PD-L1 levels.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS9109-TPS9109 ◽  
Author(s):  
Mark M. Awad ◽  
Mihaela Munteanu ◽  
Yufan Zhao ◽  
Lu Xu ◽  
Ayman Samkari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Blind Study ◽  
Double Blind Study ◽  
Small Cell Lung ◽  
First Line ◽  
Phase 3 ◽  
Double Blind

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)

Lung Cancer ◽  
2008 ◽  
Vol 60 (2) ◽  
pp. 200-207 ◽  
Author(s):  
Elizabeth A. Johnson ◽  
Randolph S. Marks ◽  
Sumithra J. Mandrekar ◽  
Shauna L. Hillman ◽  
Mark D. Hauge ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Initial Therapy ◽  
Small Cell ◽  
Blind Study ◽  
Phase Iii ◽  
Double Blind Study ◽  
Small Cell Lung ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document